IDO Inhibitor/Chemo Combo Shows Early Promise in Advanced Pancreatic Cancer
Nathan Bahary, MD, discusses results of a study that showed that the combination of indoximod with standard chemotherapy yielded a response rate of 42% as a first-line therapy for patients with metastatic pancreatic adenocarcinoma.
Palbociclib Showed Antiproliferative Activity in Early-stage Breast Cancer
Palbociclib may have antiproliferative effects when used as a neoadjuvant therapy for women with early stage breast cancer.
MAGE-A3—Targeted Adoptive T-Cell Therapy Shows Promise in Solid Tumors
A form of immunotherapy that harnesses the power of CD4 T-cells was shown to be safe and effective in patients with various types of metastatic cancers.
Ensituximab Shows Promise in Refractory mCRC
Treatment with ensituximab (NPC-1C), a chimeric IgG1
monoclonal antibody, induced stable disease in nearly
half of patients with chemotherapy-refractory metastatic
colorectal cancer without contributing significant toxicity.
Pancreatic Cancer Survival Rates Lower in Real World Than Clinical Trials
Patients with pancreatic adenocarcinoma enrolled on
clinical trials have â€œprofoundly improved survivalâ€ compared
with patients in the general population, suggesting
that oncologists who use trial data to prognosticate may
be missing the mark.
Personalized Medicine Plausible in Pancreatic Cancer
Genomic and proteomic characterization of pancreatic cancer tumors can
effectively be used to prescreen patients for clinical trials exploring molecularly
matched targeted therapies.
Zoledronic Acid Does Not Add to Upfront Docetaxel Survival Benefit in Advanced Prostate Cancer
An updated analysis of the STAMPEDE trial upholds the survival benefit observed with early use of docetaxel in advanced prostate cancer, but does not support the introduction of zoledronic acid.
2015 NCCN Guideline Updates: New Recommendations for Clinical Practice
Expert panel members highlight the latest NCCN guideline recommendations.
Lanreotide Effective in Pancreatic NET Subgroup
Lanreotide improved progression-free survival and resulted in more disease control compared with an observation strategy among patients with pancreatic neuroendocrine tumors.
Expanded NAPOLI-1 Analysis Further Characterizes MM-398 Benefit in Metastatic Pancreatic Cancer
Expanded analysis of the NAPOLI-1 trial's per-protocol population continues to support the benefit of adding the nanoliposomal encapsulation of irinotecan MM-398 to 5-fluorouracil plus leucovorin for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine.
Updated KEYNOTE-012 Shows Activity for Pembrolizumab in Gastric Cancer
Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.
Adding Trastuzumab to Fulvestrant Prolongs Responses in Metastatic Breast Cancer
The addition of trastuzumab to fulvestrant prolonged responses compared with fulvestrant alone for certain patients with metastatic breast cancer.
Novel Clinical Trial "Graduates" Two Promising Agents
The first results from the I-SPY 2 trial, which is evaluating novel agents in the neoadjuvant treatment of breast cancer, show encouraging possibilities for veliparib (ABT-888) and neratinib (PB272).
RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'
Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.
Novel Trial Design Shows Early Value for Veliparib/Carboplatin in TNBC
The first results from the novel the I-SPY 2 trial show encouraging possibilities for a veliparib/carboplatin combination therapy in TNBC.
Carboplatin Improves pCR More Than Bevacizumab in TNBC
The addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response rates in patients with triple-negative breast cancer.
Benefits of Screening Mammography Not So Inconsistent, After All
The benefit of screening mammography is more consistent across studies than has previously been thought, according to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium.
Dual HER2 Blockade Less Effective in PI3KCA-Mutant Breast Cancer
Breast cancer patients with PI3KCA mutations are less likely to achieve a pathological complete response from dual HER2 blockade in the neoadjuvant setting.
Survival Benefit Observed With Cetuximab in RAS Wild-Type Colorectal Cancer
Cetuximab plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mutations.
OS Comparable for Panitumumab and Cetuximab in KRAS Wild-Type mCRC
Panitumumab proved noninferior to cetuximab in extending overall survival in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.